Vivoryon Therapeutics N.V. recently disclosed the top-line findings from its Phase 2b European VIVIAD trial of varoglutamstat (PQ912), an oral glutaminyl cyclase (QPCT) inhibitor being explored for early Alzheimer’s disease (AD). Regrettably, the study did not meet its primary objective, failing to exhibit a significant difference in cognitive improvement over time. Secondary endpoints assessing cognition, daily living activities, and EEG global theta power were also not achieved.

Despite these disappointing results, varoglutamstat demonstrated a safety profile similar to placebo, with no significant adverse events noted. Vivoryon is now conducting a comprehensive analysis of the data, including the examination of additional endpoints and specific patient subgroups. CEO Frank Weber expressed appreciation to the participants and investigators while acknowledging the study's meticulous design.

Varoglutamstat targets toxic Abeta species N3pE by inhibiting the enzyme QPCT involved in their formation. It is being investigated for its potential as a disease-modifying therapy and has received Fast Track designation from the FDA. However, it has not yet received approval from regulatory authorities.

The VIVIAD trial involved 259 participants with mild cognitive impairment and mild AD. While the primary focus was on working memory and attention, secondary endpoints encompassed various cognitive assessments, daily living activities, and EEG measures.

 

Source: globenewswire.com

Report Abuse